TPX2在非肌层浸润性膀胱癌中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2022.01.006

癌变·畸变·突变 ›› 2022, Vol. 34 ›› Issue (1): 30-34.doi: 10.3969/j.issn.1004-616x.2022.01.006

TPX2在非肌层浸润性膀胱癌中的表达及其临床意义

彭友彬¹, 林浩¹, 黎明¹, 黄海花²

1. 汕头大学医学院第二附属医院泌尿外科, 广东汕头 515065;
2. 汕头大学医学院第二附属医院病理科, 广东汕头 515065

收稿日期:2021-07-05 修回日期:2021-12-09 出版日期:2022-01-31 发布日期:2022-02-15
通讯作者: 黄海花,E-mail:wuxiuqian7311@qq.com E-mail:wuxiuqian7311@qq.com
作者简介:彭友彬,E-mail:260881293@qq.com
基金资助:
汕头市医疗卫生科技计划项目（汕府科[2020]58号-31）

Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer

PENG Youbin¹, LIN Hao¹, LI Ming¹, HUANG Haihua²

1. Department of Urology, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515065;
2. Department of Pathology, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515065, Guangdong, China

Received:2021-07-05 Revised:2021-12-09 Online:2022-01-31 Published:2022-02-15

摘要/Abstract

摘要： 目的： 研究Xklp2靶蛋白（TPX2）在非肌层浸润性膀胱癌中的表达及其临床意义。方法： 通过挖掘GEPIA数据库中的研究数据，对TPX2 mRNA在膀胱癌组织中的表达及其与患者生存的关系进行分析；采用免疫组织化学染色检测TPX2蛋白在60例非肌层浸润性膀胱癌石蜡标本组织中的表达，并分析其表达与肿瘤临床病理指标和患者预后的关系。结果： GEPIA数据库分析提示TPX2 mRNA在膀胱癌组织中的表达较正常组织升高（P<0.05），且TPX2 mRNA高表达组患者的无病生存率较低表达组患者降低（P<0.05）；免疫组织化学染色检测结果显示TPX2蛋白在非肌层浸润性膀胱癌组织中的阳性表达率为75%（45/60），而在对应的基底组织中，TPX2蛋白表达均为阴性，二者之间的差异具有统计学意义（P<0.01）；且TPX2的表达水平与患者肿瘤数目、肿瘤直径、病理分级及术后复发等病理指标有关（P<0.05），生存分析提示TPX2高表达的膀胱癌患者的生存期较低表达者短（P<0.05）。结论： TPX2在非肌层浸润性膀胱癌中表达上调，且其表达水平较高的患者预后较差，TPX2可能作为预测非肌层浸润性膀胱癌患者预后的肿瘤标记物。

关键词: 膀胱癌, Xklp2靶蛋白, 临床病理指标, 预后

Abstract: OBJECTIVE: To investigate expression of Xklp2 target protein (TPX2) in non-muscle-invasive bladder cancer and its clinical significance. METHODS: Data from the GEPIA database were analyzed to confirm expression of TPX2 mRNA in bladder cancer and its relationship with survival of patients. In addition,immunohistochemical staining was also used to detect the expression of TPX2 protein in 60 non-muscle-invasive bladder cancer tissues. Their relationships with clinical pathological indicator of tumors and prognosis of patients were analyzed. RESULTS: By mining the GEPIA database,TPX2 mRNA expressions were up-regulated in bladder cancer,and patients with higher expressions had lower disease-free survival rate (P<0.05). Immunohistochemical staining results showed that positive expression rate of TPX2 protein was 75% (45/60),while no positive expression was found in the corresponding basal tissues. The difference between the two groups was statistically significant (P<0.01). Expression levels of TPX2 protein were negatively correlated with clinical pathological indicators of tumors such as tumor numbers,tumor diameters,pathological grades and postoperative recurrences (P<0.05). Survival analyses showed that bladder cancer patients with higher expression of TPX2 had shorter survival time (P<0.05). CONCLUSION: Expression of TPX2 was up-regulated in bladder cancer and its expression level was negatively correlated with prognosis of patients. Therefore,it has potential to become a tumor marker for predicting prognosis in bladder cancer patients.

Key words: bladder cancer, Xklp2 target protein, clinical pathological indicator, prognosis

中图分类号:

R737.14

彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.

PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.

参考文献

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
[2] ANTONI S, FERLAY J, SOERJOMATARAM I, et al. Bladder cancer incidence and mortality:a global overview and recent trends[J]. Eur Urol, 2017, 71(1):96-108.
[3] KAUFMAN D S, SHIPLEY W U, FELDMAN A S. Bladder cancer[J]. Lancet, 2009, 374(9685):239-249.
[4] BERDIK C. Unlocking bladder cancer[J]. Nature, 2017, 551(7679):S34-S35.
[5] JOHNSON S C, MCCLELLAND S E. Watching cancer cells evolve through chromosomal instability[J]. Nature, 2019, 570(7760):166-167.
[6] TIJHUIS A E, JOHNSON S C, MCCLELLAND S E. The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity[J]. Mol Cytogenet, 2019, 12:17.
[7] HEIDEBRECHT H J, BUCK F, STEINMANN J, et al. p100:a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M[J]. Blood, 1997, 90(1):226-233.
[8] VAN GIJN S E, WIERENGA E, VAN DEN TEMPEL N, et al. TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells[J]. Oncogene, 2019, 38(6):852-867.
[9] ZOU J, HUANG R Y, JIANG F N, et al. Overexpression of TPX2 is associated with progression and prognosis of prostate cancer[J]. Oncol Lett, 2018, 16(3):2823-2832.
[10] GLASER Z A, LOVE H D, GUO S H, et al. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma[J]. Urol Oncol:Semin Orig Investig, 2017, 35(5):286-293.
[11] TANG Z, LI C, KANG B, et al. GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(w1):W98-W102.
[12] SONG S M, MARU D M, AJANI J A, et al. Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma[J]. Cancer Res, 2013, 73(7):2159-2169.
[13] VICENTE J J, WORDEMAN L. The quantification and regulation of microtubule dynamics in the mitotic spindle[J]. Curr Opin Cell Biol, 2019, 60:36-43.
[14] HARRISON L E, BLEILER M, GIARDINA C. A look into centrosome abnormalities in colon cancer cells, how they arise and how they might be targeted therapeutically[J]. Biochem Pharmacol, 2018, 147:1-8.
[15] OU S R, TAN M H, WENG T, et al. LIM kinase1 regulates mitotic centrosome integrity via its activity on dynein light intermediate chains[J]. Open Biol, 2018, 8(6):170202.
[16] ALFARO-ACO R, PETRY S. How TPX2 helps microtubules branch out[J]. Cell Cycle, 2017, 16(17):1560-1561.
[17] BAYLISS R, SARDON T, VERNOS I, et al. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle[J]. Mol Cell, 2003, 12(4):851-862.
[18] LI S, LIU X, LIU T, et al. Identification of biomarkers correlated with the TNM staging and overall survival of patients with bladder cancer[J]. Front Physiol, 2017, 8:947.
[19] JIANG P Y, SHEN K X, WANG X R, et al. TPX2 regulates tumor growth in human cervical carcinoma cells[J]. Mol Med Rep, 2014, 9(6):2347-2351.
[20] ZOU Z, ZHENG B, LI J, et al. TPX2 level correlates with cholangiocarcinoma cell proliferation, apoptosis, and EMT[J]. Biomed Pharmacother, 2018, 107:1286-1293.

TPX2在非肌层浸润性膀胱癌中的表达及其临床意义

Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[2]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[3]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[4]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[5]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[6]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[7]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[8]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.
[9]	丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣. 多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究[J]. 癌变·畸变·突变, 2020, 32(6): 464-468,489.
[10]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[11]	邵俊国, 焦文静, 王雪晓, 张金艳, 马鸣. miR-429和Bmi-1 mRNA在肺癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 369-373.
[12]	陶燕, 李兰兰, 卢建中, 刘善辉, 付生军, 张静. 基于生物信息学数据库探讨FOXO3基因在膀胱癌中的表达及临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 374-379.
[13]	吕燕萍, 吴传城, 杨双凤, 何陈周, 韩仁杰, 颜伟, 刘宝英. 胃癌差异表达miRNA及其相关基因的单核苷酸多态性与胃癌预后的相关性研究[J]. 癌变·畸变·突变, 2020, 32(5): 380-386.
[14]	郭秀娟, 杜彦艳, 颜晰, 赵学涛, 韩丽娜, 武一鹏, 王雪晓, 马鸣. CREB在食管鳞癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 387-390,394.
[15]	朱依青, 张彤彤, 郑珺文, 郝佳洁, 蔡岩, 王明荣, 梁建伟, 张钰. p-mTOR蛋白在结直肠癌组织中的表达及患者预后判断中的价值[J]. 癌变·畸变·突变, 2020, 32(3): 161-165.